Literature DB >> 2927083

High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits.

J J Badimon1, L Badimon, A Galvez, R Dische, V Fuster.   

Abstract

The effects of in vivo administration of high density lipoprotein-very high density lipoprotein (HDL-VHDL) on the development of aortic fatty streaks were studied in cholesterol-fed rabbits. The rabbits received a 0.5% cholesterol-rich diet for 8 weeks. During this period, the HDL-VHDL group was intravenously administered with 50 mg/week of homologous HDL-VHDL protein; the control group received normal saline (0.9% NaCl). HDL-VHDL fraction was obtained at density range 1.063 to 1.25 gm/ml by ultracentrifugation of normal rabbit plasma. Along the study, plasma lipid levels followed a similar profile in both groups. At the completion of the study, atherosclerotic-like lipid-rich lesions covered 37.9 +/- 6% (X +/- SEM) of the intimal aortic surface in the control group, and 14.9 +/- 2.1% in the treated group (p less than 0.001). The values of total and free cholesterol, esterified cholesterol, and phospholipids deposited within vessel wall were significantly lower in the aortas of the HDL-VHDL treated group than those in the control group. Cholesterol accumulation in the livers was also significantly lower (p less than 0.01) in the treated group than in the control. We concluded that administration of homologous HDL-VHDL lipoprotein fraction to cholesterol-fed rabbits, dramatically inhibited the extent of aortic fatty streaks and lowered lipid deposition in the arterial wall and liver without modification of the plasma lipid levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2927083

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  53 in total

1.  Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  An integrated approach for the mechanisms responsible for atherosclerotic plaque regression.

Authors:  Andrew A Francis; Grant N Pierce
Journal:  Exp Clin Cardiol       Date:  2011

3.  Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells.

Authors:  V M Atger; M de la Llera Moya; G W Stoudt; W V Rodrigueza; M C Phillips; G H Rothblat
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 4.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

Review 5.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 6.  Cholesteryl Ester Transfer Protein Inhibitors - Future Soon to be REVEALed.

Authors:  Christopher Huggins; Nicoletta Charolidi; Gillian W Cockerill
Journal:  Eur Cardiol       Date:  2015-07

Review 7.  Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol.

Authors:  Stephen J Nicholls; Kiyoko Uno; E Murat Tuzcu; Steven E Nissen
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

Review 8.  Evacetrapib.

Authors:  Stephen J Nicholls
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

9.  Age-related influence of the HDL receptor SR-BI on synaptic plasticity and cognition.

Authors:  Eric H Chang; Attilio Rigotti; Patricio T Huerta
Journal:  Neurobiol Aging       Date:  2007-08-23       Impact factor: 4.673

10.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.